Syneos Health Acquires Illingworth Research Group

December 18, 2020

Syneos Health has announced the acquisition of Illingworth Research Group. Illingworth Research provides in-home and on-site research nursing services for clinical trials in more than 46 countries for the biopharmaceutical and medical device industries. With experience across Phase I–IV studies and a range of therapeutic areas including oncology, respiratory, rare disease and pediatrics, the Company also provides patient-focused CRO services.

“The patient-focused solutions provided by Illingworth Research have never been more relevant as healthcare continues to move closer to the patient. COVID-19 has accelerated this need, benefiting patients who can continue to participate in trials from their homes and sponsors seeking new options built to boost enrollment rates,” said Alistair Macdonald, Chief Executive Officer of Syneos Health.

Illingworth Research Group will maintain its brand, operating as a distinct Syneos Health Business Unit.

For more information, click here.